BenevolentAI Logo

BenevolentAI

Applies artificial intelligence to accelerate drug discovery and development.

BAI | AS

Overview

Corporate Details

ISIN(s):
LU2355630455
LEI:
2221003P54KEDC3P4Z33
Country:
United Kingdom
Address:
4-8 Maple Street, W1T 5HD London

Description

BenevolentAI is a clinical-stage company that specializes in applying artificial intelligence (AI) and machine learning to drug discovery and development. The company utilizes its proprietary technology platform, which is built upon a comprehensive knowledge graph, to analyze vast amounts of complex biomedical information. This platform is designed to generate novel biological insights, identify new therapeutic targets, and accelerate the research and development process for new medicines. By integrating advanced AI with scientific expertise, BenevolentAI aims to decipher complex disease biology and improve the efficiency and success rate of bringing new treatments to patients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-12 12:12
BAI EGM Results APPROVED
English 169.9 KB
2025-02-06 07:00
Merger-Delisting and Notice of EGM FINAL APPROVED copy
English 95.2 KB
2024-12-11 13:17
BenevolentAI unveils major strategic overhaul with return to original mission
English 440.5 KB
2024-12-11 07:00
241211_BenevolentAI Statement_FINAL
English 440.5 KB
2024-12-03 13:36
Regulatory Announcement - Issue of Equity and TVR (RSU Settlement) 03122024
English 111.3 KB
2024-10-17 07:00
241017 BenevolentAI_Leadership update_Final
English 384.6 KB
2024-09-23 14:15
Major Shareholding Notification (LINK) - 13 September 2024 rev
English 494.2 KB
2024-09-19 07:00
240919_BAI Interims 24 press release_FINAL
English 468.9 KB
2024-07-30 12:56
PDMR Notification - Dr. Joerg Moeller
English 56.6 KB
2024-07-03 07:00
BAI_LEADERSHIP TEAM CHANGE_FINAL_03.07.2024
English 140.6 KB
2024-05-02 15:30
AGM Results 2 May 2024 FINAL
English 129.2 KB
2024-05-01 12:37
Major Holdings Notification (Annex A) ABG-ODY-BAI LIMITED
English 62.7 KB
2024-04-23 07:00
Business Update 23 April 24 FINAL
English 166.2 KB
2024-04-17 07:00
BAI_Publication of the Revised Agenda for the 2024 AGM_FINAL_17.04.24
English 69.7 KB
2024-04-15 07:00
BAI_PROPOSED CHANGES TO BOARD COMPOSITION _FINAL_15.04.24
English 168.4 KB

Automate Your Workflow. Get a real-time feed of all BenevolentAI filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BenevolentAI

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BenevolentAI via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aptahem AB Logo
A clinical-stage biotech developing aptamer-based drugs for life-threatening conditions.
Sweden
APTA
APTAMER GROUP PLC Logo
Develops custom affinity binders for research, diagnostics, and therapeutics.
United Kingdom
APTA
Aptevo Therapeutics Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for cancer.
United States of America
APVO
Biotech firm providing MICROPIG models, bio-resources, and non-clinical CRO services.
South Korea
149300
Aran Research & Development (1982) Ltd. Logo
A product design and development firm providing services from concept to manufacturing.
Israel
ARAN
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
ARVINAS, INC. Logo
Clinical-stage biopharma developing therapeutics based on targeted protein degradation.
United States of America
ARVN
Asarina Pharma AB Logo
A biotechnology company in liquidation, formerly focused on neurosteroid therapies.
Sweden
ASAP
Atara Biotherapeutics, Inc. Logo
Develops off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ATRA
An integrated biologics development partner offering services from DNA sequence to cell bank.
South Korea
355690

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.